Q-omics provides the consensus-scored NUP35 profile across patient tissues and cancer cell-line models. NUP35 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NUP35 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, NUP35 protein abundance shows 27,625 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where NUP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP35 survival associations across molecular data types. NUP35 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP35 RNA expression–survival associations across cancer types. High NUP35 expression shows unfavorable associations in KIRP, ACC, LIHC, UVM and LUAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NUP35 RNA expression.
This table summarizes NUP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NUP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP35 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, COAD, STAD and LIHC. The KIRC box plot shows higher NUP35 RNA expression in tumor versus normal tissue (log2 FC = +0.341, t-test p < 0.001).
This table shows molecular features associated with NUP35 in patient tissues and cancer cell lines. In patient samples, NUP35 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
